Press Release
This document provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
-
Management & FinancePartial Correction: Consolidated Financial Results for the Full Year ended March 31, 2026 (FY2025) (Japanese standard)
-
Management & FinancePartial Correction: Consolidated Financial Results for the Full Year ended March 31, 2025 (FY2024) (Japanese standard)
-
CompanyNotice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation
-
CompanyMatters Concerning Controlling Shareholders (Affiliated Companies)
-
LicensingJCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
-
Research & DevelopmentJCR Pharmaceuticals’ Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
-
Research & DevelopmentJCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
-
OtherJCR Pharmaceuticals Receives “The Prize of the Minister of Education, Culture, Sports, Science, and Technology” at the 2026 National Commendation for Invention
-
Research & DevelopmentJCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
-
Management & FinanceFY2025 Results Briefing Session - Script